Skip to main content

Understanding disease pathways and biomarker development is our expertise

SphingoTec is driven by the goal of improving patient management and reducing mortality in critically ill patients by developing first-in-class diagnostics. We follow a hypothesis-driven approach that is rooted in a profound understanding of disease biology. The research conducted at SphingoTec has identified major pathways in the evolution of critical care diseases and conditions, such as sepsis and acute kidney injury, that are big mortality drivers world-wide. The latest scientific advancements, that have resulted after conducting more than 100 clinical studies and analyzing the data of more than 100,000 patients, are revealing previous blind spots in the disease evolution and are shedding light on new pathophysiological processes.


Diagnostic tools in Sepsis

Recent research has identified new molecules that are informative and help clinicians understand the etiology of the patient’s clinical symptoms, paving the way for personalized medicine in the field of sepsis.


Learn More


Biomarkers and the management of COVID-19 patients 

The global COVID-19 pandemic has challenged health systems world-wide, with about 5% of patients requiring admission to intensive care units. Read more on the importance of novel and established biomarker assays in the management of critically ill COVID-19 patients.

Learn More